A medical ‘specialist advisory board’ has been appointed by life insurer TAL to review medical definitions and issue guidance around medical treatments.
In a statement, the company said the appointment of the board will “strengthen TAL’s medical capability”.
“The role of the specialist advisory board is to ensure TAL stays at the forefront of medical thinking for the benefit of our customers and partners,” said TAL chief executive and managing director Brett Clark.
“As TAL’s independent expert advisory service, the board will share updates on medical advancements and clinical protocols to ensure TAL’s approach to product, underwriting and claims reflects the latest medical best practice.”
According to the statement, the current board covers cardiology, respiratory conditions, neurology, neuropsychology, psychiatry, oncology, endocrinology and infectious diseases.
TAL general manager for health services Sally Phillips said the persons chosen for the board were all experienced in the fields “most relevant to life insurance and customer health”.
“The specialist advisory board is a crucial element of our medical due diligence and governance model,” she said.
“Working with research specialists will also enable TAL to be involved in cutting-edge research. This additional capability will boost our ability to continue understanding, managing and supporting the mental, physical and financial health of our customers.”
SUBSCRIBE TO THE IFA DAILY BULLETIN
- 14 Dec 2018ASIC clarifies RG 146 requirements for advisersBy Adrian Flores
- 14 Dec 2018Sargon Capital acquires listed robo adviserBy James Mitchell
- 14 Dec 2018Industry body flags CPD burden under FASEA proposalBy Adrian Flores
- 14 Dec 2018Adviser exodus creating ‘enormous opportunity’ for accountantsBy Jotham Lian
- 14 Dec 2018Advisers embracing ESG investing, says surveyBy Adrian Flores
- 13 Dec 2018AFA picks apart CPD policy from FASEABy Adrian Flores
- view all